Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (1264)	6/27/2000 12:09:00 PM
From: nigel bates	Read Replies (3) \| Respond to of 52153

Last CRGN deal seemed to have a similar emphasis - "CuraGen .... and Ono Pharmaceutical Co., Ltd., have entered into a pharmacogenomic collaboration to apply CuraGen's platform of functional genomic technologies to gain a greater understanding of how genes influence, and ultimately affect, drug efficacy and toxicity" Two threads I considered setting up (but a full time day job together with a recent familial Pokemon addiction have interfered...) were biotech litigation & biotech deal tracking....over to you tuck (g). nig

To: Biomaven who wrote (1264)	6/28/2000 1:07:00 AM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 52153

Peter: <<P.S. There certainly is some stuff well worth discussing. Like the focus of the recent MLNM deal, for example: This collaboration will focus on enhancements to predictive ADMET (absorption, distribution, metabolism, excretion and toxicity). ADMET encompasses key characteristics of a drug that affect its safety and efficacy and is the basis for many candidate failures in clinical trials. The goal of the ADMET effort will be to enhance drug development productivity by reducing the time required for chemistry and to deliver products to clinical trials with a higher probability of success.>> Understanding pharmas weakness and where they are hot is half way to productive investment. It isn't easy and takes more than simply reading press news. I also wish that could handle this better. MLNM deal show what integrated platform can do. While many thought (first me) that MLNM acquisition of the LKST is turn left to mAb focus, we now know that SMs are still hot at MLNM and required coordinated and multiple side involvement. I am now positive that their next A target is CNS company. The question is which one and for what? Miljenko